Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;97(2):567-572.
doi: 10.3233/JAD-231198.

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Leonardino A Digma  1 , Joseph R Winer  1 , Michael D Greicius  1
Affiliations

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Leonardino A Digma et al. J Alzheimers Dis. 2024.

Abstract

With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusiasm for anti-amyloid antibodies in the treatment of Alzheimer's disease. Here, we discuss three substantial limitations regarding recent anti-amyloid clinical trials: 1) there is little evidence that amyloid reduction correlates with clinical outcome, 2) the reported efficacy of anti-amyloid therapies may be explained by functional unblinding, and 3) donanemab had no effect on tau burden in its phase 3 trial. Taken together, these observations call into question the efficacy of anti-amyloid therapies.

Keywords: Alzheimer’s disease; amyloid; clinical trials; tau.

PubMed Disclaimer

Similar articles

See all similar articles

LinkOut - more resources